Resolution Therapeutics https://validator.w3.org/feed/docs/rss2.html Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 Resolution Therapeutics Nottingham is investigating a first-in-class cell treatment to help patients End Stage Liver Disease Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S. Contact us Science Pipeline Patients Resolution Therapeutics completes enrollment in Phase I/II EMERALD clinical trial evaluating RTX001 in end-stage liver disease EMERALD Clinical Study: Q&A with Dr Paul Richardson & Dr Edward Britton, Royal Liverpool University Hospital The EMERALD clinical study: an overview with Prof. Ewan Forrest, Glasgow Royal Infirmary EMERALD Clinical Study: Q&A with Dr Kushala Abeysekera, Bristol Royal Infirmary Hospital Resolution Therapeutics extends inflammatory and fibrotic disease pipeline with in vivo Regenerative Macrophage Therapy Resolution Therapeutics congratulates University of Edinburgh on positive 4-year MATCH trial data on RMT in liver cirrhosis Resolution Therapeutics to showcase key preclinical data on its Regenerative Macrophage Therapy (RMT) RTX001 in oral presentation at ASGCT 2026 Careers News Publications About us Resolution Therapeutics announces appointment of Louise Rowe as Vice President of Operations Resolution Therapeutics’ VP, Intellectual Property & Technology Strategy Eli Gilsohn named in the World International IP Review (WIPR)’s Global In-House Elite 2026 list Love Your Liver Month 2026 Resolution: Fighting fibrosis with macrophages Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025 Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease Resolution Therapeutics R&D Webinar 2024 Resolution Therapeutics R&D Webinar 2025 Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D. Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis Resolution Therapeutics Announces Regenerative Macrophage Therapy (RMT) Manufacturing Process & Candidate Testing Suite at ASGCT 2025 Cellular Origins, Cell and Gene Therapy Catapult and Resolution Therapeutics form consortium to deliver fully automated robotics CGT manufacturing platform Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain Resolution Therapeutics Announces Upcoming Presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2024 Resolution Therapeutics Appoints Bill Symonds to its Board of Directors Resolution Therapeutics and CCRM sign collaboration agreement to develop and scale up manufacturing for iPSC-derived macrophage cell therapies Resolution Therapeutics Announces the Appointment of Lisa Bright as Chair of its Board of Directors Resolution Expands its CMC Capabilities with Key Hires Amir Hefni interview at ARM’s Cell & Gene Meeting on the Mesa Resolution Appoints Liver Disease Expert, Dr Clifford A. Brass, as Chief Medical Officer Resolution Therapeutics Strengthens its Team with Senior Appointments Resolution Therapeutics Strengthens its Executive Team with the Appointment of Simon Ramsden as Chief Financial Officer Nature Medicine publishes macrophage cell therapy clinical proof of concept data from the MATCH study Resolution Therapeutics appoints Dr. Amir Hefni as Chief Executive Officer Resolution Therapeutics’ founders present clinical proof-of-concept for macrophage cell therapy in end-stage liver disease at AASLD Resolution Therapeutics to Participate in the Jefferies Global Healthcare Conference Resolution Therapeutics Announces Upcoming Scientific Presentations at EASL Congress 2024 Resolution CEO, Dr Amir Hefni, talks about upcoming EASL presentations on Optimum TV